Bharat Biotech has concluded final analysis for Covaxin efficacy as part of Phase 3 clinical trials, after evaluation of 130 confirmed cases. The company said that the vaccine had proven safe in India's largest efficay trial. The final Phase 3 pre-print data has now been published online on medRxiv.
According to this data, Covaxin's efficacy was demonstrated to be at 77.8% against symptomatic COVID-19 patients. Covaxin, the researchers explain is also effective against the far more infectious Delta variant of COVID-19.
Between November 16, 2020 and January 7, 2021 the trial recruited 25,798 participants who were 49 randomised to BBV152 or placebo groups. This included individuals aged between 18 and 98.
"We did a double-blind, randomised, multicentre, phase 3 clinical trial in 25 Indian hospitals 39 to evaluate the efficacy, safety, and immunological lot consistency of BBV152," the paper explains.
Further details awaited.
